Perrin Wilson

Perrin joined Nuvalent as Senior Vice President of Business Development & Strategy in September 2023. Perrin brings over 15 years of experience across business development and commercial functions, including leading deals from research stage to company acquisitions and integrations, championing brand strategy and product launches.

Before joining Nuvalent, Perrin held positions of increasing responsibility at Forma Therapeutics/Novo Nordisk, including Head of Forma Business Development and Integration Management Office, Vice President Business Development and Senior Director Global Marketing, Sickle Cell Disease Strategy. At Forma, Perrin served as the deal lead for the Novo Nordisk acquisition and the out-licensing of Forma’s oncology portfolio to three different partners (both pre-and post-acquisition close). Following the acquisition, Perrin partnered with the Novo Nordisk team and led the integration from the Forma side and served as the alliance manager for the oncology deals. In her commercial role, Perrin was responsible for developing the first global brand plan for Forma’s lead molecule, etavopivat, and supported ex-US and lifecycle management strategy.

Earlier in her career, Perrin spent seven years at Takeda in various business development and commercial roles. During this time, she was responsible for several transactions to strengthen Takeda’s oncology pipeline, including the acquisition of ARIAD. Additionally, Perrin served as the integration lead for ARIAD post-acquisition and led global pre-launch preparations for Takeda’s MDS/AML program, pevonedistat. Prior to Takeda, Perrin served as a Product Manager at Forest Laboratories Canada Inc, where she launched Forest’s first product in the Canadian market, and as Senior Manager of Business Development at Forest Laboratories’ New York City base where she supported a number of transactions to augment Forest’s cardiometabolic pipeline.

Perrin received a Bachelor of Science degree in biology from Lafayette College and a Ph.D. in biomedical sciences from The Rockefeller University.